Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 52 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenic Psychoses Clear all
Completed Phase 2 Interventional Results available

Repetitive Transcranial Magnetic Stimulation for "Voices"

NCT00004980
View directory record Official record
Conditions
Schizophrenia
Interventions
repetitive transcranial magnetic stimulation (rTMS), sham stimulation
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia

NCT02203838
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

Varenicline Effects In Schizophrenic Smokers

NCT00548470
View directory record Official record
Conditions
Schizophrenia, Tobacco Use Disorder, Nicotine Dependance
Interventions
Varenicline
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Cognitive Training and Enhanced Supported Employment in Schizophrenia

NCT00339170
View directory record Official record
Conditions
Schizophrenia
Interventions
Computer-Based Cognitive Enhancement Training Program, Work Therapy Program
Behavioral
Lead sponsor
Yale University
Other
Eligibility
20 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 30, 2026, 9:08 AM EDT
Terminated Phase 2 Interventional

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

NCT00734435
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
zonisamide SR plus olanzapine, Placebo plus olanzapine
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
National City, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 4 Interventional

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

NCT00034801
View directory record Official record
Conditions
Depression, Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, ziprasidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
30
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic

NCT02128919
View directory record Official record
Conditions
Schizophrenia, Cognition, Cigarette Smoking
Interventions
tDCS
Device
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

NCT00088465
View directory record Official record
Conditions
Schizophrenic Disorders, Schizoaffective Disorder
Interventions
Intramuscular olanzapine depot
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 76 Years
Enrollment
931 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
21
States / cities
Orange, California • Pasadena, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 30, 2026, 9:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence

NCT01037075
View directory record Official record
Conditions
Schizophrenia, Drug Abuse/Dependency
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT02658357
View directory record Official record
Conditions
Schizophrenia, Schizo-affective Disorder
Interventions
Risperidone Implant
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 30, 2026, 9:08 AM EDT
Completed No phase listed Observational

fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia

NCT01046526
View directory record Official record
Conditions
Schizophrenia, Psychopathology, Nicotine Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

NCT00488319
View directory record Official record
Conditions
Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
Interventions
Paliperidone ER
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
14
States / cities
Cerritos, California • San Diego, California • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

NCT00254202
View directory record Official record
Conditions
Schizophrenia
Interventions
Iloperidone, Ziprasidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
33
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

NCT02109562
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000, Placebo, Risperidone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
32
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Staccato Loxapine in Agitated Patients With Schizophrenia

NCT00628589
View directory record Official record
Conditions
Patients With Schizophrenia and Acute Agitation
Interventions
Inhaled loxapine 5 mg, Inhaled loxapine 10 mg, Inhaled placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome

NCT00018837
View directory record Official record
Conditions
Schizophrenia, Schizophrenic Disorder
Interventions
Community Re-Entry Program: What is Schizophrenia
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Sep 30, 2026, 9:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Circuits in Schizophrenia and Smoking

NCT01369966
View directory record Official record
Conditions
Schizophrenia, Smoking Cessation, Nicotine Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 62 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 30, 2026, 9:08 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia

NCT01123317
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT01774435
View directory record Official record
Conditions
Schizophrenia
Interventions
EN3342
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Staccato Loxapine in Agitation (Proof of Concept)

NCT00369577
View directory record Official record
Conditions
Schizophrenia
Interventions
Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Upland, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine

NCT00056498
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Risperdal
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 3 Interventional

A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

NCT01979679
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 80 mg, Lurasidone 120 mg, Lurasidone 160 mg
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

NCT01432444
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole (Abilify®) IM Depot Injection
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
119
States / cities
Dothan, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 97 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 30, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

NCT01677377
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Little Rock, Alaska • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 30, 2026, 9:08 AM EDT